Recombinant Human ECM1 Protein, CF
Recombinant Human ECM1 Protein, CF Summary
Optimal concentration depends on cell type as well as the application or research objective.
Ala20-Glu540, with a C-terminal 6-His tag
Extracellular matrix protein-1 (ECM-1) is an 85 kDa, secreted glycoprotein important in connective tissue organization (1-3). Of three identified splice variants the 540 amino acid (aa) form, ECM-1a, is the most widely expressed, with the highest expression in the placenta and heart (2). ECM-1b (415 aa) is found only in tonsil and associated with suprabasal keratinocytes (2, 4). Since ECM-1b expression is differentiation-dependent, a role in terminal keratinocyte differentiation has been suggested (4). ECM-1c (559 aa) accounts for approximately 15% of skin ECM-1 (5). Human ECM-1a contains a 19 aa signal peptide and a 521 aa secreted portion that includes an N-terminal proline-rich, cysteine-free region, two tandem repeat domains, and a C-terminal domain. There are six repeats of a CC(X7-10)C motif
(x = any aa) within the tandem repeat and C-terminal domains. These motifs are involved in ligand binding to members of the albumin family, and are expected to form two (in ECM-1b) or three (in ECM-1a) “double loop” structures (2). Mature human ECM-1a shows 69%, 71%, 72% and 76% aa identity with corresponding isoforms of mouse, rat, canine, and bovine ECM-1, respectively. ECM-1 is over-expressed in many malignant epithelial tumors and has demonstrated angiogenic activity (6, 7). A variety of ECM-1 mutations, mainly within the first tandem repeat, are considered causative of lipoid proteinosis, a condition showing thickened and irregular extracellular matrix within connective tissue (8). In the autoimmune condition lichen sclerosis, auto-antibodies mainly recognize the second tandem repeat or the
C-terminus of ECM-1 (9). These domains also bind the extracellular matrix molecules fibulin-1 and perlecan (5, 10). The phenotypes of lipoid proteinosis and lichen sclerosis support a role for ECM-1 as a “biological glue” in the dermis (1).
- Chan, I. (2004) Exp. Dermatol. 29:52.
- Smits, P. et al. (1997) Genomics 45:487.
- Bhalerao, J. et al. (1995) J. Biol. Chem 270:16385.
- Smits, P. et al. (2000) J. Invest. Dermatol. 114:718.
- Mongiat, M. et al. (2003) J. Biol. Chem. 278:17491.
- Han, Z. et al. (2001) FASEB J. 15:988.
- Wang, L. et al. (2003) Cancer Lett. 200:57.
- Hamada, T. et al. (2003) J. Invest. Dermatol. 120:345.
- Oyama, N. et al. (2004) J. Clin. Invest. 113:1550.
- Fujimoto, N. et al. (2005) Biochem. Biophys. Res. Commun. 333:1327.
Citation for Recombinant Human ECM1 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1
Authors: Z Al Shareef, H Kardooni, V Murillo-Ga, G Domenici, E Stylianaki, JH Steel, M Rabano, I Gorroño-Et, I Zabalza, M dM Vivanco, J Waxman, RM Kypta
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Protein Purification Kits
Reviews for Recombinant Human ECM1 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human ECM1 Protein, CF and earn rewards!
Have you used Recombinant Human ECM1 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image